InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System
September 08, 2020 06:30 ET
|
InspireMD
TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
InspireMD Regains Compliance with NYSE AMERICAN Listing Standards
August 10, 2020 06:30 ET
|
InspireMD
TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Second Quarter 2020 Financial Results
August 05, 2020 06:40 ET
|
InspireMD
In the second quarter the Company was granted approval to market its CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating...